Ignite Creation Date:
2025-12-24 @ 3:21 PM
Ignite Modification Date:
2025-12-25 @ 1:40 PM
Study NCT ID:
NCT07271992
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-11-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Sponsor:
First Hospital of China Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-12-14
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-12-14
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-26
First Submit QC Date:
None
Study First Post Date:
2025-12-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-26
Last Update Post Date:
2025-12-09
Last Update Post Date Type:
ESTIMATED